Last week, [GlaxoSmithKline] gave the green light to Cosmos to start producing generic versions of the [antiretroviral HIV/AIDS] drugs Epivir and Retrovir, for the three East African Community countries, as well as Rwanda and Burundi...According to Dr Prakash Patel, the chairman and chief executive of Cosmos, the new development could see the price of ARVs in the region fall by as much as 40 per cent. [also refers to Laboratory & Allied and Universal Pharmaceuticals]